Pharmion Corporation (Nasdaq: PHRM) announced the submission of a MAA with the European Medicines Agency (EMEA) for Vidaza(R) (azacitidine for inject
read more » Discuss Add this link to...Bury Add to:
| Bookmarks
Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced that the U.S. Food and Drug Administration (FDA) has designated the Companies' histone deacetylase (HDAC) inhibitor
read more » Discuss Add this link to...Bury Add to:
| Bookmarks